Korro Bio, Inc. KRRO

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
35/100
Developing

Ranked against 712 peers in Biotechnology

About Korro Bio, Inc.

Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. Its lead product candidate is KRRO-110 which is in Phase 1/2 clinical trial for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, … Full KRRO analysis →

Key strengths

  • Strong Liquidity Buffer Liquidity position is strong (score 0.66), providing operational cushion.

Key risks

  • ROIC Below WACC or Peers ROIC at 16.1th percentile suggests inefficient capital deployment.
  • Elevated Debt Risk Debt serviceability is weak (score 0.18), raising refinancing risk.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
36
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where KRRO ranks in Biotechnology

Korro Bio, Inc. ranks #442 of 713 scored companies in Biotechnology by moat score — the top 62%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

# Company Moat score Rating
438 CollPlant Biotechnologies Ltd. CLGN 35/100 Developing
439 Cytokinetics, Incorporated CYTK 35/100 Developing
440 Dianthus Therapeutics, Inc. DNTH 35/100 Developing
441 Eledon Pharmaceuticals, Inc. ELDN 35/100 Developing
442 Korro Bio, Inc. KRRO 35/100 Developing
443 Adlai Nortye Ltd. ANL 35/100 Developing
444 Oragenics Inc. OGEN 35/100 Developing
445 Fractyl Health, Inc. GUTS 35/100 Developing
446 Jasper Therapeutics, Inc. JSPR 35/100 Developing

See every Biotech / Pre-Revenue company ranked by moat score →

How KRRO scores on the Corporate Default defenses

Pricing Power

Score 36 · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Score 35 · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 40 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 20 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 36 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Score 47 · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding KRRO's moat

What is Korro Bio, Inc.'s moat score?

Korro Bio, Inc. (KRRO) scores 35 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #442 of 713 scored companies in Biotechnology, the top 62%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Scale & Market Position (47/100) and its weakest is Capital Efficiency (20/100).

How does Korro Bio, Inc. compare with other Biotechnology companies?

Korro Bio, Inc. ranks #442 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are Eledon Pharmaceuticals, Inc. (ELDN) at 35 just above it and Adlai Nortye Ltd. (ANL) at 35 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is Korro Bio, Inc. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Korro Bio, Inc.?

The Corporate Default template measures 6 defenses, and KRRO scores: Pricing Power (36), Cost Advantage (35), Customer Stickiness (40), Capital Efficiency (20), Resilience (36), Scale & Market Position (47). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000